Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,754 | $27,116 | $27,281 | $27,305 |
| % Growth | 6% | -0.6% | -0.1% | – |
| Cost of Goods Sold | $6,251 | $6,498 | $5,657 | $6,601 |
| Gross Profit | $22,503 | $20,618 | $21,624 | $20,704 |
| % Margin | 78.3% | 76% | 79.3% | 75.8% |
| R&D Expenses | $5,907 | $5,718 | $4,977 | $4,601 |
| G&A Expenses | $2,638 | $2,818 | $4,895 | $4,511 |
| SG&A Expenses | $6,091 | $6,090 | $5,673 | $5,246 |
| Sales & Mktg Exp. | $3,453 | $3,272 | $778 | $735 |
| Other Operating Expenses | $8,843 | $1,205 | $3,644 | $939 |
| Operating Expenses | $20,841 | $13,013 | $14,294 | $10,786 |
| Operating Income | $1,662 | $7,605 | $7,330 | $9,918 |
| % Margin | 5.8% | 28% | 26.9% | 36.3% |
| Other Income/Exp. Net | -$972 | -$746 | -$1,516 | -$1,640 |
| Pre-Tax Income | $690 | $6,859 | $5,814 | $8,278 |
| Tax Expense | $211 | $1,247 | $1,248 | $2,077 |
| Net Income | $480 | $5,665 | $4,592 | $6,225 |
| % Margin | 1.7% | 20.9% | 16.8% | 22.8% |
| EPS | 0.38 | 4.54 | 3.66 | 4.96 |
| % Growth | -91.6% | 24% | -26.2% | – |
| EPS Diluted | 0.38 | 4.5 | 3.64 | 4.93 |
| Weighted Avg Shares Out | 1,247 | 1,248 | 1,255 | 1,256 |
| Weighted Avg Shares Out Dil | 1,255 | 1,258 | 1,262 | 1,262 |
| Supplemental Information | – | – | – | – |
| Interest Income | $281 | $376 | $106 | $0 |
| Interest Expense | $977 | $944 | $935 | $1,001 |
| Depreciation & Amortization | $2,767 | $2,693 | $2,103 | $2,050 |
| EBITDA | $4,434 | $10,496 | $8,852 | $11,329 |
| % Margin | 15.4% | 38.7% | 32.4% | 41.5% |